Phibro Animal Health (PAHC) Q4 FY26 earnings call

Phibro Animal Health concluded a strong Q4 and FY26, achieving record net sales and significant adjusted EBITDA growth, driven by its core animal health and mineral nutrition segments. The company successfully integrated its new MFA business and completed its FIBRA Forward transformation program. Looking ahead, Phibro is navigating regulatory uncertainty in Brazil for Virginia Myosin and optimizing its manufacturing footprint, while prioritizing organic growth and strategic business development.